JAK2 and myeloproliferative disorder: Moreover, we show that a combined application of Jak2 inhibitors with Aurora kinase inhibitors recapitulates the effects observed for CEP701 and might be beneficial for the treatment of MPN patients if CEP701 fails clinical approval.